Verona Pharma plc Stock Income Statements

Verona Pharma plc Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Gross Profit

Operating Profit

Net Income

Verona Pharma plc Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31

revenue:
product sales	102,939,000	71,256,000	36,637,000	5,624,000
other revenue	199,000	5,000,000
total revenue	103,138,000	76,256,000
yoy
qoq	35.25%
operating expenses:
cost of sales	4,756,000	3,407,000	2,039,000	543,000
gross profit	98,382,000	72,849,000
yoy
qoq	35.05%
gross margin %	95.39%	95.53%
research and development	12,950,000	14,054,000	7,870,000	10,552,000	19,388,000	4,122,000	2,958,000	-2,474,000	12,610,000	6,838,000	9,838,000	14,982,000	17,625,000	22,709,000	22,560,000	20,563,000	13,574,000
selling, general and administrative	72,127,000	69,112,000	45,085,000	35,196,000	49,035,000	14,972,000	13,353,000	12,439,000	9,589,000	8,323,000	5,290,000	5,526,000	7,440,000	5,757,000	10,883,000
total operating expenses	89,833,000	86,573,000	54,994,000	46,291,000	68,423,000	19,094,000	16,311,000	9,965,000	22,199,000	15,161,000	15,128,000	20,508,000	25,065,000	28,466,000	33,443,000	28,548,000	22,856,000
operating income/	13,305,000
other income/
research and development tax credit			556,000	1,612,000	847,000	1,034,000	-309,000	-1,934,000	2,313,000	796,000	2,127,000	5,409,000	1,302,000	4,975,000	4,749,000
loss on extinguishment of debt		-407,000			-3,653,000
interest income	4,302,000	3,891,000	3,994,000	4,750,000	3,140,000	3,292,000	3,390,000	3,402,000	2,677,000	1,862,000	779,000	165,000	15,000	3,000	4,000	3,000	4,000
interest expense	-6,822,000	-10,195,000	-10,317,000	-9,882,000	-1,757,000	-623,000	-401,000	-740,000	-293,000	-230,000	-116,000	-91,000	-84,000	-85,000	-86,000	-85,000	-84,000
foreign exchange gain/	1,097,000	470,000	320,250	1,475,000	25,000			740,000	932,000
total other (expense)/income	-1,423,000	-6,241,000	-7,217,000	-2,045,000	-1,398,000					669,000	-455,000
income/(loss) before income taxes	11,882,000
income tax benefit/	39,000	239,000
net income/	11,921,000
income/(loss) per ordinary share - basic	20
income/(loss) per ordinary share - diluted	20
income/(loss) per ads - basic	140
income/(loss) per ads - diluted	130
weighted-average ordinary shares outstanding - basic	685,155,000
weighted-average ordinary shares outstanding - diluted	727,223,000
weighted-average ads outstanding - basic	85,644,000
weighted-average ads outstanding - diluted	90,903,000
operating income		-10,317,000	-18,339,000	-40,667,000	-68,423,000	-19,094,000	-16,311,000	-9,965,000	-22,199,000			-20,508,000	-25,065,000			-28,548,000	-22,856,000
yoy		-45.97%	12.43%	308.10%	208.23%			-51.41%	-11.43%			-28.16%	9.66%
qoq		-43.74%	-54.90%	-40.57%	258.35%	17.06%	63.68%	-55.11%				-18.18%				24.90%
operating margin %	0%	-13.53%
income before income taxes		-16,558,000	-25,556,000	-42,712,000	-69,821,000	-14,185,000	-14,643,000	-8,497,000	-16,570,000			-17,687,000	-24,755,000			-22,043,000	-21,210,000
net income		-16,319,000	-33,827,000	-42,962,000	-70,835,000	-14,132,000	-14,687,000	-8,807,000	-16,743,000			-17,766,000	-24,837,000			-22,068,000	-21,290,000
yoy		15.48%	130.32%	387.82%	323.07%			-50.43%	-32.59%			-19.49%	16.66%
qoq		-51.76%	-21.26%	-39.35%	401.24%	-3.78%	66.77%	-47.40%				-28.47%				3.65%
net income margin %	0%	-21.40%
loss per ordinary share - basic and diluted		-20	-55	-70	-110	-15	-20	-10	-30			-40	-50			-50	-50
weighted-average shares outstanding - basic and diluted		679,405,000	652,310,582,000	651,944,000	648,217,000	634,142,660,000	638,238,749,000	634,469,423,000	621,451,000			484,777,837,000				470,786,767,000	469,465,085,000
income tax expense			-8,271,000	-250,000	-1,014,000	53,000	-44,000	-310,000	-173,000	-56,250	-64,000	-79,000	-82,000	-58,000	-127,000	-25,000	-80,000
foreign exchange (loss)/gain						165,000	-1,012,000			3,013,000	-3,245,000	-2,662,000	-923,000	29,250	-86,000
total other income/(expense)						2,191,250	1,668,000
total other income								1,468,000	5,629,000			2,821,000	310,000	4,954,000	4,621,000	6,505,000	1,646,000
revenue															40,000,000
gross profit
yoy
qoq
gross margin %	0%	0%
operating expenses
operating (loss)/profit										-15,175,250	-15,128,000
other (expense)/income
fair value movement on warrants														2,000	40,000	2,711,000	-507,000
(loss)/profit before income taxes										-14,506,250	-15,583,000
net (loss)/profit										-14,562,500	-15,647,000
(loss)/profit per ordinary share - basic										-30	-30
(loss)/profit per ordinary share - diluted										-30	-30
weighted-average shares outstanding - basic											544,134,136,000				475,334,354,000
weighted-average shares outstanding - diluted											544,134,136,000				515,819,439,000
balance at january 1, 2022													489,177,550,000
issuance of common shares under at-the-market sales agreement													80,696,000
restricted share units vested
issuance of ordinary shares to treasury													4,800,000,000
common shares withheld for taxes on vested stock awards
equity settled share-based compensation reclassified as cash-settled
share-based compensation
balance at march 31, 2022													494,058,246,000
operating profit/														-11,211,750	6,557,000
profit/(loss) before income taxes														-8,018,750	11,178,000
net profit/														-8,076,750	11,051,000
other comprehensive profit/
foreign currency translation adjustments
total comprehensive profit/(loss) attributable to shareholders of the company														-8,076,750	11,051,000
profit/(loss) per ordinary share - basic														-17.5	20
profit/(loss) per ordinary share - diluted														-17.5	20
general and administrative																7,985,000	9,282,000
other income /
benefit from research and development tax credit																3,836,000	2,070,000
foreign exchange gain																40,000	163,000
other comprehensive loss:
total comprehensive loss attributable to shareholders of the company																-22,068,000	-21,290,000
other comprehensive (loss) / income:

We provide you with 20 years income statements for Verona Pharma plc stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Verona Pharma plc stock. Explore the full financial landscape of Verona Pharma plc stock with our expertly curated income statements.

The information provided in this report about Verona Pharma plc stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.